tocilizumab SC
Selected indexed studies
- Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. (Lancet Respir Med, 2020) [PMID:32866440]
- Trial of Tocilizumab in Giant-Cell Arteritis. (N Engl J Med, 2017) [PMID:28745999]
- Tocilizumab: A Review in Rheumatoid Arthritis. (Drugs, 2017) [PMID:29094311]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial. (2023) pubmed
- Differential Binding of Sarilumab and Tocilizumab to IL-6Rα and Effects of Receptor Occupancy on Clinical Parameters. (2021) pubmed
- Trial of Tocilizumab in Giant-Cell Arteritis. (2017) pubmed
- Tocilizumab: A Review in Rheumatoid Arthritis. (2017) pubmed
- Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. (2019) pubmed
- Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. (2020) pubmed
- Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial. (2022) pubmed
- Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). (2018) pubmed
- Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial. (2022) pubmed
- Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study. (2025) pubmed